1623 Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

1623 Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,994	Closed	-$508K	–	27
2022 Q3	$508K	Hold	5,994	–	–	0.31%	33
2022 Q2	$497K	Sell	5,994 -2,690	-31%	-$214K	0.31%	32
2022 Q1	$670K	Buy	8,684 +1,312	+18%	+$110K	0.34%	34
2021 Q4	$651K	Buy	7,372 +2,558	+53%	+$211K	0.24%	48
2021 Q3	$372K	Hold	4,814	–	–	0.15%	58
2021 Q2	$402K	Buy	4,814 +2,962	+160%	+$235K	0.15%	59
2021 Q1	$140K	Buy	+1,852	New	+$151K	0.06%	62

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

1623 Capital's BMRN Position: Q4 2022 in Review

1623 Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 5,994 shares — an estimated $508K sold.

1623 Capital first reported a position in BMRN in Q1 2021 and held it in 7 quarters. The position peaked at $670K in Q1 2022. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

1623 Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
1623 Capital sold 5,994 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $508K.
1623 Capital first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 7 quarters.
1623 Capital's BioMarin Pharmaceuticals position peaked at $670K in Q1 2022.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on 1623 Capital's 13F filing for Q4 2022, filed 10 Feb 2023.